As a first-line treatment
option in advanced
NSCLC
Studied in one of the largest clinical trials of patients with
advanced NSCLC expressing PD-L1 ≥50%1,3
LIBTAYO is indicated for the first-line treatment of patients with non–small cell lung cancer (NSCLC)
whose tumors have high PD-L1 expression [tumor proportion score (TPS) ≥50%] as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is1:
- Locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or1
- Metastatic1
Learn more >